Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by vTv Therapeutics Inc. on June 10, 2025. The filing details the outcomes of shareholder votes regarding director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes and Voting Results
Director Elections
Stockholders elected seven nominees to the Board of Directors for terms expiring at the 2026 annual meeting. All nominees received significant "For" votes, with Anne Phillips, Paul Sekhri, and Daniel K. Spiegelman receiving the highest support.
- Srinivas Akkaraju: 2,069,879 For; 116,667 Withheld
- Raymond Cheong: 2,083,009 For; 103,537 Withheld
- Fahed Al Marzooqi: 2,086,263 For; 100,283 Withheld
- Richard S. Nelson: 2,081,952 For; 104,594 Withheld
- Anne Phillips: 2,182,836 For; 3,710 Withheld
- Paul Sekhri: 2,182,196 For; 4,350 Withheld
- Daniel K. Spiegelman: 2,184,216 For; 2,330 Withheld
Each nominee had 219,013 Broker Non-Votes.
Auditor Ratification
Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- For: 2,400,291
- Against: 3,852
- Abstain: 1,416
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the term expiration dates for the newly elected directors (2026 Annual Meeting).
- Confirm the engagement of Ernst & Young LLP for the fiscal year ending December 31, 2025.
- Review the proxy statement for the 2025 Annual Meeting to understand the background of the director nominees and the rationale for the auditor selection.
- Check subsequent filings (e.g., 10-K or 10-Q) for the financial metrics absent in this 8-K.